Biodesix Inc.
BDSX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BDSX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BDSX
Biodesix Inc. is a diagnostic solutions company focused on lung disease, combining multi-omic data with clinical insights to personalize patient care.
Key risk: Negative equity
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials for Biodesix Inc..
Biodesix Inc. is a diagnostic solutions company focused on lung disease, combining multi-omic data with clinical insights to personalize patient care.
- Cash and equivalents of $30.1M as of 2026-06-30 [sec].
- Total revenue of $26.9M for the six months ended 2026-06-30 [sec].
- Net loss of $7.3M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of -$2.5M as of 2026-06-30 [sec].
- Total debt of $96.8M as of 2026-06-30 [sec].
What works
- Revenue growth: Diagnostic Testing revenue increased 18% year-over-year in Q1 2025 [sec_mda · as of 2025-05-13].
- Expanding biopharma partnerships: The company sees opportunities in companion diagnostic development and novel target discovery using multi-omic data [sec_mda · as of 2026-02-26].
- Continued investment in sales force and R&D to drive adoption and innovation [sec_mda · as of 2026-08-05].
What to weigh
- Negative shareholders' equity of -$2.5M as of 2026-06-30 indicates accumulated deficits exceeding assets [sec].
- High total debt of $96.8M as of 2026-06-30 relative to cash and revenue [sec].
- Net loss of $7.3M for the six months ended 2026-06-30 shows ongoing unprofitability [sec].
- Dependence on attracting and retaining biopharmaceutical customers for growth, which poses execution risk [sec_mda · as of 2026-08-05].
Risks & what to watch (4)›
Key risks
- Negative equity — Shareholders' equity of -$2.5M as of 2026-06-30 indicates liabilities exceed assets [sec].
- High debt burden — Total debt of $96.8M as of 2026-06-30 is substantial relative to cash and revenue [sec].
- Ongoing net losses — Net loss of $7.3M for the six months ended 2026-06-30 shows continued unprofitability [sec].
- Customer concentration risk — Revenue growth depends on attracting and retaining biopharmaceutical customers [sec_mda · as of 2026-08-05].
What to watch
- Revenue growth trajectory, especially Diagnostic Testing revenue trends [sec_mda · as of 2025-05-13].
- Ability to reduce net losses and achieve profitability [sec].
- Progress in expanding biopharma partnerships and development services [sec_mda · as of 2026-08-05].
- Management of debt levels and liquidity position [sec].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Biodesix Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Biodesix Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
65.5 months
D/E 9.43 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
35
Total value held
$22.5M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 510,322 | $7.4M |
| marshall wace, llp | 141,636 | $2.1M |
| stempoint capital lp | 140,008 | $2.0M |
| essex investment management co llc | 132,086 | $1.9M |
| trexquant investment lp | 69,601 | $1.0M |
| geode capital management, llc | 49,998 | $726K |
| two sigma investments, lp | 45,231 | $656K |
| perkins capital management inc | 44,783 | $649K |
| sei investments co | 43,024 | $624K |
| legato capital management llc | 41,174 | $597K |
Showing top 10 of 35 institutional holders of Biodesix Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 2.6%
- Days to cover
- 2.6
- Shares short
- 148,012
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BDSX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Biodesix Inc.?
Biodesix Inc. is a diagnostic solutions company focused on lung disease, combining multi-omic data with clinical insights to personalize patient care.
Who is the CEO of Biodesix Inc.?
Mr. Scott Hutton is the chief executive officer of Biodesix Inc. (BDSX).
Where is Biodesix Inc. headquartered?
Biodesix Inc. (BDSX) is headquartered in Louisville, CO, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.